Target Inhibition in Antiangiogenic Therapy A Wide Spectrum of Selectivity and Specificity (Q37816164)

23 August 2017

1 reference

title

Target inhibition in antiangiogenic therapy a wide spectrum of selectivity and specificity (English)

1 reference

23 August 2017

Target Inhibition in Antiangiogenic Therapy A Wide Spectrum of Selectivity and Specificity (English)

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

19 November 2024

main subject

angiogenesis inhibitor

1 reference

Olivier Rixe

1 reference

23 August 2017

Colleen Darnell

1 reference

23 August 2017

Ronan J. Kelly

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21131797

19 November 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21131797

19 November 2024

publication date

1 November 2010

1 reference

23 August 2017

November 2010

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21131797

full work available at URL

19 November 2024

https://journals.lww.com/10.1097/PPO.0b013e3181ff37cf

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

19 November 2024

1 reference

23 August 2017

1 reference

23 August 2017

1 reference

23 August 2017

page(s)

635-642

1 reference

Pathways mediating resistance to vascular endothelial growth factor-targeted therapy

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ.

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Molecular diversity of VEGF-A as a regulator of its biological activity.

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Vascular endothelial growth factor: basic science and clinical progress

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Effect of mechanical stretch on HIF-1{alpha} and MMP-2 expression in capillaries isolated from overloaded skeletal muscles: laser capture microdissection study

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Roles for VEGF in the adult.

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Endothelial cells and VEGF in vascular development

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Vascular endothelial growth factor localization in the adult.

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1/2 and Akt pathways.

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Stretch-induced VEGF expression in the heart

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

The role of neuropilins in cancer

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Distribution of VEGF and flt-1 in the normal dog tissues.

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Preparing the "soil": the premetastatic niche

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Combined targeted therapies in non-small cell lung cancer: a winner strategy?

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Engineering antibodies for therapy

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

VEGF-targeted therapy: mechanisms of anti-tumour activity.

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Renal side effects of anti-VEGF therapy in man: a new test system.

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Role of the VEGF--a signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

VEGF inhibition and renal thrombotic microangiopathy

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Therapeutic potential of inhibitory VEGF splice variants.

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy.

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

A quantitative analysis of kinase inhibitor selectivity

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Technology evaluation: VEGF Trap (cancer), Regeneron/sanofi-aventis.

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

VEGF-Trap: a VEGF blocker with potent antitumor effects

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Thrombotic microangiopathy and anti-VEGF agents

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Oxygen sensing by HIF hydroxylases

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Hypoxia-inducible factors in the kidney

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Expression of hypoxia-inducible transcription factors in developing human and rat kidneys.

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Notch signalling: a simple pathway becomes complex

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Regulation of angiogenesis by homotypic and heterotypic notch signalling in endothelial cells and pericytes: from basic research to potential therapies

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Suppression of p53 by Notch in lymphomagenesis: implications for initiation and regression

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia.

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Focal segmental glomerulosclerosis: recent advances

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Notch inhibition reverses kidney failure

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

The Notch pathway in podocytes plays a role in the development of glomerular disease

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Notch2, but not Notch1, is required for proximal fate acquisition in the mammalian nephron.

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Tumor angiogenesis: therapeutic implications

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

Vascular zip codes in angiogenesis and metastasis

19 November 2024

1 reference

https://api.crossref.org/works/10.1097/PPO.0B013E3181FF37CF

19 November 2024

Identifiers

DOI

1 reference

23 August 2017

1 reference